TY - JOUR
T1 - Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis
AU - Santos Moreno, Pedro
AU - García Salinas, Rodrigo
AU - Caballero Uribe, Carlo Vinicio
AU - Brance, María Lorena
AU - Marín Zúcaro, Nicolas M.
AU - Arrieta Vega, Dina
AU - Beltrán, Adriana
AU - Cabrera, Sonia
AU - Chacon Diaz, Rosa
AU - Corbacho, Inés
AU - Felipe Diaz, Oscar Jair
AU - Gamboa, Rocio
AU - Gobbi, Carla
AU - Guerra Bautista, Generoso
AU - Kakehasi, Adriana María
AU - Linhares, Fernanda
AU - Medina, Yimy F.
AU - Monge Zeledón, Pablo
AU - Ramagli, Alicia
AU - Stange, Lilith
AU - Stekman, Yvan
AU - Vargas, Sara
AU - Ferreira, Gilda
AU - Fernández Ávila, Daniel Gerardo
AU - Brun, Lucas R.
AU - Zamora, Natalia
AU - Cardiel Ríos, Mario Humberto
AU - Citera, Gustavo
AU - Mysler, Eduardo
AU - Toro Gutiérrez, Carlos Enrique
AU - Xavier, Ricardo
AU - Soriano, Enrique Roberto
N1 - Publisher Copyright:
© 2026 Elsevier Ltd.
PY - 2026/1
Y1 - 2026/1
N2 - The Pan American League of Associations for Rheumatology has developed evidence-based recommendations for the pharmacological management of rheumatoid arthritis in Latin America. A panel of rheumatoid arthritis experts from Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Peru, Uruguay, and Venezuela formulated clinically relevant questions in the population, intervention, comparator, outcome format. Systematic literature reviews were done following the Grading of Recommendations Assessment, Development and Evaluation method. Recommendations were formulated based on evidence quality and expert consensus, which required at least 70% agreement among the voting members to be included in the guidelines. Ten recommendations and a treatment algorithm were developed. Key topics include early initiation of conventional synthetic disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, parenteral methotrexate for intolerance, cautious glucocorticoid use, switching mechanisms of action after unsuccessful biological or targeted synthetic DMARD treatment, tapering in remission, and guidance for rheumatoid arthritis-associated interstitial lung disease and vasculitis. Special attention is given to cost-effectiveness and accessibility considering the socioeconomic characteristics of Latin America. These recommendations aim to support clinicians in Latin America by providing a practical, evidence-based, and contextually relevant framework that addresses the unique challenges faced in the region.
AB - The Pan American League of Associations for Rheumatology has developed evidence-based recommendations for the pharmacological management of rheumatoid arthritis in Latin America. A panel of rheumatoid arthritis experts from Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Peru, Uruguay, and Venezuela formulated clinically relevant questions in the population, intervention, comparator, outcome format. Systematic literature reviews were done following the Grading of Recommendations Assessment, Development and Evaluation method. Recommendations were formulated based on evidence quality and expert consensus, which required at least 70% agreement among the voting members to be included in the guidelines. Ten recommendations and a treatment algorithm were developed. Key topics include early initiation of conventional synthetic disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, parenteral methotrexate for intolerance, cautious glucocorticoid use, switching mechanisms of action after unsuccessful biological or targeted synthetic DMARD treatment, tapering in remission, and guidance for rheumatoid arthritis-associated interstitial lung disease and vasculitis. Special attention is given to cost-effectiveness and accessibility considering the socioeconomic characteristics of Latin America. These recommendations aim to support clinicians in Latin America by providing a practical, evidence-based, and contextually relevant framework that addresses the unique challenges faced in the region.
UR - https://www.scopus.com/pages/publications/105024886853
U2 - 10.1016/s2665-9913(25)00259-0
DO - 10.1016/s2665-9913(25)00259-0
M3 - Review article
AN - SCOPUS:105024886853
SN - 2665-9913
VL - 8
SP - e53-e65
JO - The Lancet Rheumatology
JF - The Lancet Rheumatology
IS - 1
ER -